Candice Clarke1,2, Maria Prendecki3,2, Amrita Dhutia2, Mahrukh A Ali2, Hira Sajjad2, Oshini Shivakumar2, Liz Lightstone1,2, Peter Kelleher4,5, Matthew C Pickering1, David Thomas1,2, Rawya Charif2, Megan Griffith2, Stephen P McAdoo1,2, Michelle Willicombe1,2. 1. Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, Hammersmith Campus, London, United Kingdom. 2. Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United Kingdom. 3. Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, Hammersmith Campus, London, United Kingdom m.prendecki@imperial.ac.uk. 4. Immunology of Infection Group, Department of Infectious Diseases, Imperial College London, London, United Kingdom. 5. Department of Infection and Immunity, North West London Pathology NHS Trust, London, United Kingdom.
Abstract
BACKGROUND: Strategies to minimize the risk of transmission and acquisition of COVID-19 infection in patients with ESKD receiving in-center hemodialysis have been rapidly implemented across the globe. Despite these interventions, confirmed COVID-19 infection rates have been high in the United Kingdom. Prevalence of asymptomatic disease in an adult hemodialysis population has not been reported. Also, to our knowledge, the development of humoral response to SARS-CoV-2 has not been previously reported in this population. Although serologic testing does not provide information on the infectivity of patients, seroprevalence studies may enable investigation of exposure within dialysis units and hence, assessment of current screening strategies. METHODS: To investigate the seroprevalence of SARS-CoV-2 antibodies in a hemodialysis population, we used the Abbott IgG assay with the Architect system to test serum samples from 356 patients receiving in-center hemodialysis for SARS-CoV-2 antibodies. RESULTS: Of 356 patients, 121 had been symptomatic when screened before a dialysis session and received an RT-PCR test; 79 (22.2% of the total study population) tested positive for COVID-19. Serologic testing of all 356 patients found 129 (36.2%) who tested positive for SARS-CoV-2 antibodies. Only two patients with PCR-confirmed infection did not seroconvert. Of the 129 patients with SARS-CoV-2 antibodies, 52 (40.3%) had asymptomatic disease or undetected disease by PCR testing alone. CONCLUSIONS: We found a high seroprevalence of SARS-CoV-2 antibodies in patients receiving in-center hemodialysis. Serologic evidence of previous infection in asymptomatic or PCR-negative patients suggests that current diagnostic screening strategies may be limited in their ability to detect acute infection.
BACKGROUND: Strategies to minimize the risk of transmission and acquisition of COVID-19infection in patients with ESKD receiving in-center hemodialysis have been rapidly implemented across the globe. Despite these interventions, confirmed COVID-19infection rates have been high in the United Kingdom. Prevalence of asymptomatic disease in an adult hemodialysis population has not been reported. Also, to our knowledge, the development of humoral response to SARS-CoV-2 has not been previously reported in this population. Although serologic testing does not provide information on the infectivity of patients, seroprevalence studies may enable investigation of exposure within dialysis units and hence, assessment of current screening strategies. METHODS: To investigate the seroprevalence of SARS-CoV-2 antibodies in a hemodialysis population, we used the Abbott IgG assay with the Architect system to test serum samples from 356 patients receiving in-center hemodialysis for SARS-CoV-2 antibodies. RESULTS: Of 356 patients, 121 had been symptomatic when screened before a dialysis session and received an RT-PCR test; 79 (22.2% of the total study population) tested positive for COVID-19. Serologic testing of all 356 patients found 129 (36.2%) who tested positive for SARS-CoV-2 antibodies. Only two patients with PCR-confirmed infection did not seroconvert. Of the 129 patients with SARS-CoV-2 antibodies, 52 (40.3%) had asymptomatic disease or undetected disease by PCR testing alone. CONCLUSIONS: We found a high seroprevalence of SARS-CoV-2 antibodies in patients receiving in-center hemodialysis. Serologic evidence of previous infection in asymptomatic or PCR-negative patients suggests that current diagnostic screening strategies may be limited in their ability to detect acute infection.
Authors: Melissa M Arons; Kelly M Hatfield; Sujan C Reddy; Anne Kimball; Allison James; Jesica R Jacobs; Joanne Taylor; Kevin Spicer; Ana C Bardossy; Lisa P Oakley; Sukarma Tanwar; Jonathan W Dyal; Josh Harney; Zeshan Chisty; Jeneita M Bell; Mark Methner; Prabasaj Paul; Christina M Carlson; Heather P McLaughlin; Natalie Thornburg; Suxiang Tong; Azaibi Tamin; Ying Tao; Anna Uehara; Jennifer Harcourt; Shauna Clark; Claire Brostrom-Smith; Libby C Page; Meagan Kay; James Lewis; Patty Montgomery; Nimalie D Stone; Thomas A Clark; Margaret A Honein; Jeffrey S Duchin; John A Jernigan Journal: N Engl J Med Date: 2020-04-24 Impact factor: 91.245
Authors: Catherine F Houlihan; Nina Vora; Thomas Byrne; Dan Lewer; Gavin Kelly; Judith Heaney; Sonia Gandhi; Moira J Spyer; Rupert Beale; Peter Cherepanov; David Moore; Richard Gilson; Steve Gamblin; George Kassiotis; Laura E McCoy; Charles Swanton; Andrew Hayward; Eleni Nastouli Journal: Lancet Date: 2020-07-09 Impact factor: 79.321
Authors: Meng Yuan; Nicholas C Wu; Xueyong Zhu; Chang-Chun D Lee; Ray T Y So; Huibin Lv; Chris K P Mok; Ian A Wilson Journal: Science Date: 2020-04-03 Impact factor: 47.728
Authors: Regina Konrad; Ute Eberle; Alexandra Dangel; Bianca Treis; Anja Berger; Katja Bengs; Volker Fingerle; Bernhard Liebl; Nikolaus Ackermann; Andreas Sing Journal: Euro Surveill Date: 2020-03
Authors: Diana Rodríguez-Espinosa; José Jesús Broseta; Elena Cuadrado; Francisco Maduell Journal: J Am Soc Nephrol Date: 2020-09-29 Impact factor: 10.121
Authors: Dalvir Kular; Irina Chis Ster; Alexander Sarnowski; Eirini Lioudaki; Dandisonba C B Braide-Azikiwe; Martin L Ford; David Makanjuola; Alexandra Rankin; Hugh Cairns; Joyce Popoola; Nicholas Cole; Mysore Phanish; Richard Hull; Pauline A Swift; Debasish Banerjee Journal: Kidney360 Date: 2020-09-10
Authors: Johan De Meester; Dirk De Bacquer; Maarten Naesens; Bjorn Meijers; Marie M Couttenye; An S De Vriese Journal: J Am Soc Nephrol Date: 2020-11-05 Impact factor: 10.121